Silverback Therapeutics, Inc. SBTX

Institutional shares held 70.4 Million

218K calls

329K puts

Total value of holdings $0

$0 calls

$0 puts

Market Cap N/A

Institutional ownership 198.34%

# of Institutions 180

We take great care to ensure that the data presented and summarized in this overview for Silverback Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.

Quarterly Institutional Activity in SBTX

Shares Bought

Shares Sold

View Transactions

Top Institutions Holding SBTX

View all

Latest Institutional Activity in SBTX

Top Purchases

Q1 2025

Janney Montgomery Scott LLC Shares Held: 449K ($0)

422K Shares purchased

1552.07% Added

Q1 2025

Rhumbline Advisers Shares Held: 69.8K ($0)

4.6K Shares purchased

7.06% Added

Q1 2025

Future Financial Wealth Managment LLC Shares Held: 1K ($0)

1K Shares purchased

New Holding

Q1 2025

Versant Capital Management, Inc Shares Held: 622 ($0)

622 Shares purchased

New Holding

Q1 2025

Farther Finance Advisors, LLC Shares Held: 536 ($0)

290 Shares purchased

117.89% Added

View All Buyers

Top Sells

Q1 2025

Sg Americas Securities, LLC Shares Held: 36.4K ($0)

14.8K Shares sold

28.86% Reduced

Q1 2025

Gamma Investing LLC Shares Held: 267 ($0)

3.09K Shares sold

92.05% Reduced

Q4 2024

Franklin Resources Inc Shares Held: 1.98M ($0)

861K Shares sold

30.34% Reduced

Q4 2024

Deerfield Management Company, L.P. (Series C) Shares Held: 10.5M ($0)

563K Shares sold

5.08% Reduced

Q4 2024

Jacobs Levy Equity Management, Inc Shares Held: 101K ($0)

552K Shares sold

84.47% Reduced

View All Sellers

About SBTX

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Insider Transactions at SBTX

Insider Transaction List

View all

Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
Apr 07 2025	Laura Shawver	SELL Open market or private sale	Direct	50,002 -19.21%	$600,024 $12.3 P/Share
Apr 07 2025	Laura Shawver	BUY Exercise of conversion of derivative security	Direct	50,002 +9.18%	$200,008 $4.85 P/Share
Mar 20 2025	Eric Karas Chief Commercial Officer	SELL Open market or private sale	Direct	10,000 -56.51%	$140,000 $14.0 P/Share
Mar 20 2025	Eric Karas Chief Commercial Officer	BUY Exercise of conversion of derivative security	Direct	10,000 +36.11%	$10,000 $1.5 P/Share
Mar 06 2025	Laura Shawver	SELL Open market or private sale	Direct	49,600 -19.08%	$545,600 $11.21 P/Share
Mar 06 2025	Laura Shawver	BUY Exercise of conversion of derivative security	Direct	49,600 +16.02%	$198,400 $4.85 P/Share
Mar 05 2025	Laura Shawver	SELL Open market or private sale	Direct	400 -0.19%	$4,400 $11.0 P/Share
Mar 05 2025	Laura Shawver	BUY Exercise of conversion of derivative security	Direct	400 +0.19%	$1,600 $4.85 P/Share
Feb 03 2025	Laura Shawver	SELL Open market or private sale	Direct	50,000 -19.21%	$600,000 $12.31 P/Share
Feb 03 2025	Laura Shawver	BUY Exercise of conversion of derivative security	Direct	50,000 +8.78%	$200,000 $4.0 P/Share
Jan 06 2025	Laura Shawver	SELL Open market or private sale	Direct	50,000 -19.21%	$550,000 $11.1 P/Share
Jan 06 2025	Laura Shawver	BUY Exercise of conversion of derivative security	Direct	50,000 +16.11%	$150,000 $3.15 P/Share
Dec 17 2024	Richard E Lowenthal PRESIDENT AND CEO	SELL Open market or private sale	Indirect	100,000 -4.03%	$1,100,000 $11.67 P/Share
Dec 17 2024	Sarina Tanimoto CHIEF MEDICAL OFFICER	SELL Open market or private sale	Indirect	100,000 -4.03%	$1,100,000 $11.67 P/Share
Dec 13 2024	Justin Chakma Chief Business Officer	SELL Open market or private sale	Direct	27,272 -16.66%	$327,264 $12.06 P/Share
Dec 13 2024	Justin Chakma Chief Business Officer	BUY Exercise of conversion of derivative security	Direct	27,272 +14.28%	$27,272 $1.44 P/Share
Dec 12 2024	Brian Dorsey Chief Operating Officer	SELL Open market or private sale	Direct	25,000 -80.58%	$300,000 $12.3 P/Share
Dec 12 2024	Brian Dorsey Chief Operating Officer	BUY Exercise of conversion of derivative security	Direct	25,000 +44.62%	$0 $0.64 P/Share
Dec 12 2024	Justin Chakma Chief Business Officer	SELL Open market or private sale	Direct	117,333 -46.25%	$1,407,996 $12.27 P/Share
Dec 12 2024	Justin Chakma Chief Business Officer	BUY Exercise of conversion of derivative security	Direct	117,333 +31.62%	$0 $0.84 P/Share

View All Transactions

Last 12 Months Summary

Buy / Acquisition

2.68M Shares

From 8 Insiders

Exercise of conversion of derivative security	1.35M shares
Bona fide gift	1.33M shares

Sell / Disposition

13.2M Shares

From 12 Insiders

Open market or private sale	6.58M shares
Bona fide gift	4M shares
Other acquisition or disposition	2.67M shares

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SBTX shares.

Notify only if

Value

Any

Insider Trading

Get notified when an Silverback Therapeutics, Inc. insider buys or sells SBTX shares.

Notify only if

Operation

Any

Value

Any

Type

P - Open market or private purchase×

S - Open market or private sale×

V - Transaction voluntarily reported earlier than required×

A - Grant, award, or other acquisition×

D - Sale (or disposition) back to the issuer×

F - Payment of exercise price or tax liability×

I - Discretionary transaction×

M - Exercise of conversion of derivative security×

C - Conversion of derivative security×

E - Expiration of short derivative position×

H - Expiration (or cancellation) of long derivative position with value received×

O - Exercise of out-of-the-money derivative securities×

X - Exercise of in-the-money or at-the-money derivatives securities×

G - Bona fide gift×

L - Small Acquisition×

W - Acquisition or disposition by will or laws×

Z - Deposit into or withdrawal from voting trust×

J - Other acquisition or disposition×

K - Transaction in equity swap or similar instrument×

U - Disposition due to a tender of shares in a change of control transaction×

20 item(s) selected

News

Receive news related to Silverback Therapeutics, Inc.

Track Activities on SBTX

Account

Silverback Therapeutics, Inc. SBTX

Quarterly Institutional Activity in SBTX

Top Institutions Holding SBTX

Latest Institutional Activity in SBTX

Top Purchases

Top Sells

About SBTX

Insider Transactions at SBTX

Insider Transaction List

Last 12 Months Summary

Track Institutional and Insider Activities on SBTX

Institutional Portfolio Updates

Insider Trading

News